Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

August

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

24

Exagen Inc. Appoints Paul Kim to Board of Directors

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

15

Exagen Inc. Reports First Quarter 2023 Results

Record Physician Demand for AVISE® CTD SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN)(“Exagen”), a...

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a...

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,...

14

Exagen Inc. Reports Third Quarter 2022 Results

Medicare Reimbursement Returns SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of...

17

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN) announced today that the company has...

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Dr. Concoff to lead rheumatoid arthritis medical initiatives SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) —...

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

4

Exagen Inc. Reports Second Quarter 2022 Results

Records in AVISE® CTD Volume, Ordering Healthcare Providers and Adopters SAN DIEGO, Aug. 04, 2022 (GLOBE...

4

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

TIGER study to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue...

5

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

AVISE® Lupus more clinically effective than current standard of care SAN DIEGO, July 05, 2022 (GLOBE...

Recent developments

News

August

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

July

24

Exagen Inc. Appoints Paul Kim to Board of Directors

May

15

Exagen Inc. Reports First Quarter 2023 Results

March

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

January

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

November

14

Exagen Inc. Reports Third Quarter 2022 Results

October

17

Exagen Announces Appointment of John Aballi as CEO

October

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

August

4

Exagen Inc. Reports Second Quarter 2022 Results

August

4

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

July

5

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility